It would also be a helpful resource for newly-diagnosed patients and their physicians as well. Amazon Giveaway allows you to run promotional giveaways in order to create buzz, reward your audience, and attract new followers and customers.
Brain tumors across the age spectrum: biology, therapy, and late effects
Learn more about Amazon Giveaway. Set up a giveaway. There's a problem loading this menu right now. Learn more about Amazon Prime. Get fast, free shipping with Amazon Prime. Get to Know Us. English Choose a language for shopping. Not Enabled Word Wise: Not Enabled Enhanced Typesetting: Amazon Music Stream millions of songs. Amazon Advertising Find, attract, and engage customers. Amazon Drive Cloud storage from Amazon. Alexa Actionable Analytics for the Web. AmazonGlobal Ship Orders Internationally.
Introduction
Amazon Inspire Digital Educational Resources. Amazon Rapids Fun stories for kids on the go. Amazon Restaurants Food delivery from local restaurants. ComiXology Thousands of Digital Comics. East Dane Designer Men's Fashion. Shopbop Designer Fashion Brands.
Long term side effects of radiotherapy
Withoutabox Submit to Film Festivals. Amazon Renewed Refurbished products with a warranty. Amazon Second Chance Pass it on, trade it in, give it a second life. Response shifts are natural changes in a patient's perception of their QOL over time in response to changing internal standards when they are faced with a life-threatening illness.
If these natural changes and adaptations over time are not considered, data from longitudinal QOL studies may incorrectly attribute changes in QOL to other external factors. Research on accounting for this phenomenon is still ongoing, and models to account for response shift have been proposed. Finally, because the symptoms and realms of QOL can be interrelated e. The large number of interdependent variables may explain why many QOL studies have produced mixed results.
The best way to account for these interactions in a trial is to have a focused question that is prospectively measured and ideally compared between adequately powered randomized groups in order to reduce the number of confounders. Several exciting avenues of research remain in the vastly unexplored area of QOL in brain tumor patients. Research needs to be performed on validation of easy-to-use questionnaires and cognitive tests with incorporation of these instruments into ongoing clinical trials.
Moreover, a better description of longitudinal QOL and exploration into specific causes of symptoms and survivorship is necessary. In addition, the significance of other nontraditional patient factors that contribute to QOL, such as caregiver, spiritual, and financial aspects of a patient's life, need to be better explored.
Finally, once QOL in brain tumor patients has been adequately described, interventions—both pharmacologic and nonpharmacologic—are necessary in order to improve QOL. Ultimately, the exploration of imaging, serum, genetic, or other biomarkers that can more objectively quantify symptoms not only will allow the field of QOL to be more consistently described, but also will likely have significant diagnostic, prognostic, and treatment value.
While funding may be limited to pursue these primary QOL research goals, efforts should be made to incorporate QOL research as secondary end points into ongoing therapy trials. Few trials have done this to date, 94 although the potential impact of QOL on survival and prognosis makes incorporation of QOL end points especially important. QOL in brain tumor patients is complex and multidimensional in nature, with symptoms having interrelationships with each other as well as patient, tumor, and treatment factors. Assessing QOL is challenging given the scarcity of well-validated instruments, difficulty with compliance especially in longitudinal measurements over time, and the lack of well-designed trials.
Assessing QOL in brain tumor patients is additionally complicated by the relative rarity of the disease compared to other malignancies, functional limitations to self-reporting, and concurrent medications such as steroids and antiepileptics. Despite these limitations, some conclusions can be made regarding QOL studied to date on brain tumor patients. Specifically, the burden of symptoms that affect QOL is significant, but understudied. There are limited therapeutic options to improve QOL. The incorporation of QOL as both primary and secondary end points is crucial because QOL can have prognostic value, and improvement of QOL may in turn increase overall survival.
As such, QOL should be included as a secondary outcome measure and also be tested as a primary outcome measure in intervention studies designed to improve the lives of brain tumor patients. Clearly, more work is needed in the field of QOL in brain tumor patients. Adequately powered, high-quality studies from descriptive to diagnostic to interventional in nature are needed in order to increase both the quality and quantity of these patients' lives. Oxford University Press is a department of the University of Oxford. It furthers the University's objective of excellence in research, scholarship, and education by publishing worldwide.
Sign In or Create an Account. Close mobile search navigation Article navigation. A Common Etiology to Symptoms: Quality of life in adults with brain tumors: Current knowledge and future directions Raymond Liu.
- Hyperbaric oxygen as an adjunctive therapy in treatment of malignancies, including brain tumours.
- Product details;
- Brain Tumor Treatment.
Address correspondence to Susan M. Abstract Quality of life is an important area of clinical neurooncology that is increasingly relevant as survivorship increases and as patients experience potential morbidities associated with new therapies. View large Download slide. Advances in quality of life measurements in oncology patients.
Impact of brain tumour treatment on quality of life. Effect of disease burden on health-related quality of life in patients with malignant gliomas. Neurobehavioral status and health-related quality of life in newly diagnosed high-grade glioma patients. Prospective study of quality of life in adults with newly diagnosed high-grade gliomas. Prospective study of neuropsychologic testing and quality-of-life assessment of adults with primary malignant brain tumors. Quality of life in brain tumor patients.
Facets and determinants of quality of life in patients with recurrent high grade glioma. J Neurol Neurosurg Psychiatry. A prospective study of quality of life in adults with newly diagnosed high-grade gliomas: Cognitive functions and quality of life in patients with low-grade gliomas: The relationship between function, quality of life and coping in patients with low-grade gliomas. Epilepsy in low-grade gliomas: Cognitive function after radiotherapy for supratentorial low-grade glioma: Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: Prognostic factors for survival in adult patients with cerebral low-grade glioma.
Survival, prognostic factors, and therapeutic efficacy in low-grade glioma: Effect of brain tumour laterality on patients' perceived quality of life. Predicting major depression in brain tumor patients. Health-related quality of life in patients with glioblastoma: Self-reported comprehensive health status of adult brain tumor patients using the Health Utilities Index. Supratentorial low-grade glioma in adults: Supratentorial low grade astrocytoma: Depression and functional outcome in patients with brain tumors: Depression in patients with high-grade glioma: Evaluation and characterization of generalized anxiety and depression in patients with primary brain tumors.
Quality of life in brain tumor patients: Gender difference in relation to depression and quality of life among patients with a primary brain tumor. Depression in relation to survival among neurosurgical patients with a primary brain tumor: Decreased quality of life and depression as predictors for shorter survival among patients with low-grade gliomas: Eur Arch Psychiatry Clin Neurosci.
Mechanisms of peritumoural brain dysfunction: Expression of serotonin receptors in human fetal astrocytes and glioma cell lines: Taphoorn MJ, Klein M. Cognitive deficits in adult patients with brain tumours. Cognitive deficits before treatment among patients with brain tumors. Multifaceted end points in brain tumor clinical trials: The prognostic value of cognitive functioning in the survival of patients with high-grade glioma.
Detrimental effects of tumor progression on cognitive function of patients with high-grade glioma. Clinical prognostic factors affecting survival in patients with newly diagnosed glioblastoma multiforme GBM [abstract]. Importance of baseline Mini-Mental State Examination as a prognostic factor for patients with low-grade glioma. The use of the Mini-Mental State Examination to assess cognitive functioning in cancer trials: Cognitive functioning in long-term survivors of high-grade glioma. Effects of treatment on long-term survivors with malignant astrocytomas.
Neuropsychologic impairment in adults with brain tumors. Am J Clin Oncol. Quality of life in patients with stable disease after surgery, radiotherapy, and chemotherapy for malignant brain tumour. Psychometric- and quality-of-life assessment in long-term glioblastoma survivors. Survival and quality of life after interstitial implantation of removable high-activity iodine sources for the treatment of patients with recurrent malignant gliomas. Which glioblastoma multiforme patient will become a long-term survivor?
Long-term survival in adult hemispheric glioma: Clin Oncol R Coll Radiol. Surviving glioblastoma for more than 5 years: Giovagnoli AR, Boiardi A. Cognitive impairment and quality of life in long-term survivors of malignant brain tumors. Ital J Neurol Sci. Symptom clusters in cancer patients and their relation to EGFR ligand modulation of the circadian axis.
Symptom clusters in oncology patients and implications for symptom research in people with primary brain tumors. Symptom clusters in patients with high-grade glioma. Effects of radiation and chemotherapy on cognitive function in patients with high-grade glioma. Relationship between fatigue and quality of life in patients with glioblastoma multiformae.
Phase II study of donepezil in irradiated brain tumor patients: Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threomethylphenidate HCl in brain tumor patients receiving radiation therapy. Pilot study of modafinil for treatment of neurobehavioral dysfunction and fatigue in adult patients with brain tumors. Using the theory of planned behavior to understand the determinants of exercise intention in patients diagnosed with primary brain cancer.
Complementary therapy use and quality of life in persons with high-grade gliomas. Complementary and alternative medicine use and quality of life in patients with primary brain tumors. J Pain Symptom Manage. Long-term effects of cognitive training on everyday functional outcomes in older adults. The use of a simple Likert scale to measure quality of life in brain tumor patients. Anxiety and depression in patients with an intracranial neoplasm before and after tumour surgery. The effect of brain tumour laterality on anxiety levels among neurosurgical patients.
Neuropsychiatric manifestations of right hemisphere lesions. Mood changes after surgery for tumors of the cerebral cortex. Cognitive dysfunction following surgery for intracerebral glioma: Prediction of neurocognitive outcome in adult brain tumor patients. Neuropsychological impairments associated with lesions caused by tumor or stroke. Neurobehavioral sequelae of cranial irradiation in adults: Neuropsychometric evaluation of long-term survivors of adult brain tumours: Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by the Folstein Mini-Mental State Examination.
Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: Adverse long-term effects of brain radiotherapy in adult low-grade glioma patients. Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide.
Cognitive side effects of medications.
Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials. Quality of life of brain tumor patients. Quality of life in patients with intracranial tumors on the basis of Karnofsky's Performance Status. Quality of life self-reports from brain tumor patients: The Karnofsky Performance Status scale. An examination of its reliability and validity in a research setting.
Quantitative measurement of quality outcome in malignant glioma patients using an independent living score ILS. Assessment of a retrospective cohort. The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Development of a brain subscale and revalidation of the general version FACT-G in patients with primary brain tumors.
Validation of single-item linear analog scale assessment of quality of life in neuro-oncology patients. Validation of the M. Cognitive function as a predictor of survival in patients with recurrent malignant glioma. Practical problems with the collection and interpretation of serial quality of life assessments in patients with malignant glioma.
The clinical significance of adaptation to changing health: